In vitro susceptibility of Aspergillus spp. clinical isolates to albendazole | Zendy

Nicolás Berthet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro susceptibility of Aspergillus spp. clinical isolates to albendazole

Author(s) -

Nicolás Berthet

Publication year - 2003

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkg245

Subject(s) - aspergillus flavus , aspergillus , aspergillus terreus , microbiology and biotechnology , aspergillus niger , aspergillus fumigatus , albendazole , biology , aspergillosis , benzimidazole , itraconazole , in vitro , antifungal , chemistry , food science , botany , biochemistry , ecology , organic chemistry

The in vitro antifungal activity of albendazole, a benzimidazole widely used as an antihelmintic drug in humans, was investigated and assessed for its activity against Aspergillus spp. Forty-eight isolates, representing the most frequent species found in human pathology [Aspergillus fumigatus (n = 27), Aspergillus flavus (n = 10), Aspergillus terreus (n = 7), Aspergillus nidulans (n = 3) and Aspergillus niger (n = 1)], and one quality control strain (A. niger ATCC 9804 83435) were tested according to the NCCLS M38-P methodology for moulds. All the strains were susceptible to albendazole, with homogeneous MICs for each species; three strains were resistant to itraconazole.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research